메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Ascletis Announces the Combination of ASC47 and ASC31, its…

- Combination of a low dose of ASC47 with ASC31, a novel peptide agonist targeting both GLP-1 receptor (GLP-1R) and GIP receptor (GIPR), resulted in a 44.8% reduction in body weight after 14 days of treatment in a diet-induced obese (DIO) mouse model. - Combination of a low dose of ASC47 with ASC31 demonstrated statistically significantly greater efficacy than a combination of a low dose of ASC47 with tirzepatide, 44.8% compared to 38.1%, respectively, in the DIO mouse model. HONG KONG, Aug. 18, 2025 -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces encouragi
- 김갑성 기자
- 2025-08-18 08:15
GenScript Biotech Demonstrates Profitable Scale and Strateg…

[ 메디채널 김갑성 기자 ] Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation PISCATAWAY, N.J., Aug. 17, 2025 -- GenScript Biotech Corporation (HK.1548), a global pioneer in life sciences innovation, today announced outstanding interim results for the first half of 2025, underscoring its ability to deliver profitable growth at scale through strategic globalization, differentiated technology, and relentless innovation. Fueled by robust demand across all business segments and expansion into key international markets, GenScript achie
- 김갑성 기자
- 2025-08-17 20:01
VARON's Lung Health Awareness Initiative Urges Proactive Step…

NEW YORK, Aug. 15, 2025 -- With allergy and flu season approaching, VARON is calling on individuals to take preventive measures to protect their lungs. Through its "Every Breath Counts" initiative, the oxygen concentrator manufacturer is partnering with respiratory health experts to share practical lung care strategies and introduce tools — from at home oxygen concentrators to lightweight portable oxygen concentrators — to help people maintain optimal oxygen levels during seasonal flare-ups. As part of its Every Breath Counts initiative, VARON recently h
- 김갑성 기자
- 2025-08-15 23:08
BestQool Announces Summer Promotion and Fall Refresh with…

[ 메디채널 김갑성 기자 ] Summer Appreciation Sales Offers 12% Off All Products NEW YORK, Aug. 15, 2025 -- BestQool , a pioneer manufacturer of home-use red light therapy devices, is excited to unveil its latest breakthrough product – the BQ60Pro. Based on years of experience and customer feedback, this small yet powerful home-use device now provides six wavelengths for maximum therapeutic protocols, high power output, and a versatile mounting system that completely redefines flexibility in home light therapy. Ahead of the Fall release, BestQool will be holding its Summer Appre
- 김갑성 기자
- 2025-08-15 21:00
Novel Gene Therapy for ALS cleared for global trials in China…

BEIJING, Aug. 15, 2025 -- SineuGene Therapeutics Co., Ltd. ("SineuGene"), clinical-stage biotechnology company that mainly focuses on gene therapies for neurological disorders, announced today that China's National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for SNUG01, a groundbreaking gene therapy product for amyotrophic lateral sclerosis (ALS). This milestone follows a prior clearance of SNUG01's IND application by the U.S. Food and Drug Administration (FDA) in March 2025, paving the way for the initiation of a Phase I/IIa mul
- 김갑성 기자
- 2025-08-15 19:00
Saigon Technology Drives Industry-Specific AI Transformatio…

[ 메디채널 김갑성 기자 ] Vietnamese software leader leverages AI and domain expertise to help industries modernize workflows and reduce long-term tech costs. HO CHI MINH CITY, Vietnam, Aug. 15, 2025 -- As global businesses outgrow generic SaaS tools, Saigon Technology is delivering next-gen, AI-powered custom software for healthcare, fintech, logistics, and e-commerce — unlocking productivity and digital resilience. According to a 2024 report by Vietnam's Ministry of Science and Technology, digital adoption among local businesses surged from 30% in 2021 to nearly 70% in 2024. Many of t
- 김갑성 기자
- 2025-08-15 10:00
Etrasimod Receives Strong Recommendation in the ACG Clinic…

Shanghai, Aug. 15, 2025 -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that etrasimod (VELSIPITY®) has been included in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults (the "Updated Guidelines"). In patients with moderately to severely active ulcerative colitis (UC), the updated guidelines recommend S1P receptor modulators, including etrasimod, are recommended for induct
- 김갑성 기자
- 2025-08-15 09:35
CARsgen Therapeutics Announces 2025 Interim Results

SHANGHAI, Aug. 15, 2025 -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Interim Results. Business Highlights Cash and bank balances were around RMB1,261 million as of June 30, 2025. Cash and cash equivalents and deposits at the end of 2025 are expected to be not less than RMB1,100 million. We expect to have adequate cash into the 2028 excluding subsequent cash inflows. During H1 2025, certification and regulatory filings for zevor-cel have been completed in more t
- 김갑성 기자
- 2025-08-15 08:15
TraceLink Accelerates Supply Chain Transformation with Ne…

BOSTON, Aug. 14, 2025 -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the life sciences and healthcare supply chain, today announced significant new platform enhancements to drive supply chain transformation with its Orchestration Platform for Universal Solutions (OPUS). The new capabilities are designed to empower supply chain, finance, commercial, and IT leaders to master today's supply chain complexities and prepare for an agentic-first future. The platform and product releases—spanning OPUS, Multienterprise Information Network
- 김갑성 기자
- 2025-08-14 22:00
Sisram Medical will Report H1 2025 Financial Results on August…

[ 메디채널 김갑성 기자 ] H1 2025 conference call to be held on August 21, at 8:30 a.m. Eastern Time HONG KONG, Aug. 14, 2025 -- Sisram Medical Ltd (the "Company" or "Sisram", stock code: 1696.HK; together with its subsidiaries referred to as the "Group"), a global consumer wellness group featuring a first-of-its-kind synergistic ecosystem of business building blocks and consumer-focused brands, including energy-based devices, injectables, and other complementary offerings, today announced that it expects to release its financial results for H1 2025, ended June 30
- 김갑성 기자
- 2025-08-14 20:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-08-20_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 21일 01시 40분